Drug Profile
Research programme: siRNA therapeutics - sanofi-aventis/Traversa
Alternative Names: PTD-DRBDLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis; Traversa Therapeutics
- Developer Sanofi; Traversa Therapeutics
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 25 Mar 2010 Early research in Undefined indication in USA (Parenteral)